RA Capital Management L.P. Has $56.21 Million Holdings in Astria Therapeutics, Inc. (NASDAQ:ATXS)

RA Capital Management L.P. increased its holdings in Astria Therapeutics, Inc. (NASDAQ:ATXS) by 1.2% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,105,213 shares of the biotechnology company’s stock after acquiring an additional 61,457 shares during the period. RA Capital Management L.P. owned about 9.05% of Astria Therapeutics worth $56,208,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Quest Partners LLC raised its holdings in shares of Astria Therapeutics by 3,310.6% in the 2nd quarter. Quest Partners LLC now owns 3,206 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 3,112 shares during the last quarter. PDT Partners LLC acquired a new stake in shares of Astria Therapeutics in the 3rd quarter worth about $140,000. SG Americas Securities LLC purchased a new stake in Astria Therapeutics in the 3rd quarter valued at about $155,000. Hsbc Holdings PLC purchased a new stake in Astria Therapeutics in the 2nd quarter valued at about $171,000. Finally, Price T Rowe Associates Inc. MD purchased a new stake in Astria Therapeutics in the 1st quarter valued at about $200,000. Institutional investors and hedge funds own 98.98% of the company’s stock.

Analysts Set New Price Targets

Several research firms have commented on ATXS. Wedbush reiterated an “outperform” rating and issued a $22.00 price objective on shares of Astria Therapeutics in a research note on Tuesday, August 13th. Oppenheimer increased their price objective on shares of Astria Therapeutics from $26.00 to $28.00 and gave the company an “outperform” rating in a research note on Thursday, November 14th. HC Wainwright reiterated a “buy” rating and issued a $16.00 price objective on shares of Astria Therapeutics in a research note on Thursday, November 14th. Finally, Evercore ISI upgraded shares of Astria Therapeutics to a “strong-buy” rating in a research note on Wednesday, August 14th. Five research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Astria Therapeutics has a consensus rating of “Buy” and a consensus price target of $25.60.

Astria Therapeutics Stock Down 0.9 %

Astria Therapeutics stock opened at $10.14 on Thursday. Astria Therapeutics, Inc. has a twelve month low of $4.75 and a twelve month high of $16.90. The firm has a 50 day moving average price of $11.02 and a 200-day moving average price of $10.65. The company has a market capitalization of $572.24 million, a P/E ratio of -4.85 and a beta of 0.67.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.